Additionally, participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of 10%, 15%, 20%, and 25%
Several participants reflected on improvements in a range of physical health issues including breathlessness, back pain, frequent urination and urine infections, sleep, and skin problems
This is a common challenge in long-term clinical research: life circumstances, illness, or logistical issues can interfere with compliance
Which non-genetic considerations does the dosing table list
These improvements appear to occur primarily through weight loss and reduction in ectopic fat deposition in liver and muscle tissue, rather than through direct insulin-sensitizing effects on cellular receptors
When this happens, peptide therapy can be helpful